Marx Biotechnology

Company Overview

Snapshot

Founded in January 2011 by Stephen Marx Ph.D., Marx Biotechnology operates with 1–10 employees. The company has secured $1.22M in total capital across four funding rounds. In September 2019, the company received a grant from EU Horizon 2020.

Business overview

Marx Biotechnology (MBT) is a Health Tech & Life Sciences company focused on developing diagnostic solutions. The company's core technology is a blood test designed to diagnose the early onset of graft-versus-host disease (GVHD) by monitoring molecular functions, aiming to provide rapid results to physicians. MBT also leverages a big data platform to diagnose various diseases, monitor patient conditions, and guide treatment decisions. The company serves the healthcare industry, specifically targeting laboratories and providers with its medical devices and diagnostics.

Company Intelligence Q&A

When was Marx Biotechnology founded?

Marx Biotechnology was founded in January 2011.

Who is the founder of Marx Biotechnology?

Stephen Marx Ph.D. is the founder and CEO of Marx Biotechnology.

What is Marx Biotechnology's primary focus?

Marx Biotechnology primarily focuses on developing a blood test for the early diagnosis of graft-versus-host disease (GVHD).

What is the total capital raised by Marx Biotechnology?

Marx Biotechnology has raised a total of $1.22M across four funding rounds.

Did Marx Biotechnology receive any grants?

In September 2019, Marx Biotechnology received a grant from EU Horizon 2020.